Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1140407

registered interest
date	18/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle the overcharging of medicines to the NHS.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	279026
answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The costs of branded medicines are controlled by the statutory and voluntary schemes for branded medicines. Under those schemes, any price increase needs to be agreed by the Department. For generic medicines, the Department encourages competition between suppliers to drive prices down. This generally works well but there are instances where there is no or not enough competition and prices appear unreasonably high. Section 262 of the National Health Service Act 2006 enables the Secretary of State to limit the price of any medicine not covered by the voluntary scheme for branded medicines. The Department is preparing a public consultation on the use of this power for generic medicines. The Health Service Products (Provision and Disclosure of Information) Regulations 2018 support the powers in the National Health Service Act 2006 by enabling the Secretary of State to require suppliers to provide information about their products including information about the cost of manufacturing those products.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279028 question first answered 23/07/2019 16:46:17 answering member 4455 label Biography information for Seema Kennedy
tabling member	4249 label Biography information for Anne Marie Morris

1140408

registered interest
date	18/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tetracosactide: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is aware that synacthen has recently increased in cost from £2.70 per vial to £38 per vial; and if he will make a statement.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	279027
answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The Department agreed the list price increase for Synacthen in March 2015.</p><p>The previous Pharmaceutical Price Regulation Scheme, the current 2019 Voluntary Scheme for Branded Medicines Pricing and Access and our statutory branded medicines pricing scheme all have detailed arrangements for how companies can request an increase to the National Health Service list price for a product.</p><p>Companies must comply with the rules of the relevant scheme when making a price increase request and all price increase requests must receive Departmental approval before they can take effect.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 23/07/2019 16:53:15 answering member 4455 label Biography information for Seema Kennedy
tabling member	4249 label Biography information for Anne Marie Morris

1140411

registered interest
date	18/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department will use the Health Service Products (Provision and Disclosure of Information) Regulations 2018 to prevent price inflation of medicines.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	279028
answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The costs of branded medicines are controlled by the statutory and voluntary schemes for branded medicines. Under those schemes, any price increase needs to be agreed by the Department. For generic medicines, the Department encourages competition between suppliers to drive prices down. This generally works well but there are instances where there is no or not enough competition and prices appear unreasonably high. Section 262 of the National Health Service Act 2006 enables the Secretary of State to limit the price of any medicine not covered by the voluntary scheme for branded medicines. The Department is preparing a public consultation on the use of this power for generic medicines. The Health Service Products (Provision and Disclosure of Information) Regulations 2018 support the powers in the National Health Service Act 2006 by enabling the Secretary of State to require suppliers to provide information about their products including information about the cost of manufacturing those products.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279026 question first answered 23/07/2019 16:46:17 answering member 4455 label Biography information for Seema Kennedy
tabling member	4249 label Biography information for Anne Marie Morris

1140412

registered interest
date	18/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle the promotion of red listed drugs to non-specialist healthcare professionals by pharmaceutical companies.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	279029
answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The Medicines and Healthcare products Regulatory Agency investigates, or appropriately refers to another medicines self-regulatory body, complaints from any source about medicines advertising in relation to compliance with United Kingdom legislation.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 23/07/2019 16:39:00 answering member 4455 label Biography information for Seema Kennedy
tabling member	4249 label Biography information for Anne Marie Morris

1132034

registered interest
date	13/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Primary Care Networks: Rural Areas
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has carried out a rural proofing review of the implementation of primary care networks.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	264405
answer	answer is ministerial correction date of answer 21/06/2019 answer text <p>Recognising the specific circumstances faced by some rural practices, there are additional flexibilities. NHS England has explicitly allowed rurality as an exception for meeting the definition of a Primary Care Networks. As set out in the Network Contract Direct Enhanced Service (DES) (under paragraph 3.2) commissioners may waiver the 30,000 minimum population “where a PCN serves a natural community which has a low population density across a large rural and remote area”. Further information is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/03/network-contract-des-specification-2019-20-v1.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/03/network-contract-des-specification-2019-20-v1.pdf</a></p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 21/06/2019 11:16:38 answering member 4455 label Biography information for Seema Kennedy
tabling member	4249 label Biography information for Anne Marie Morris

1132036

registered interest
date	13/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Primary Care Networks
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what criteria his Department plans to use to assess Primary Care Networks’ engagement with local communities.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	264407
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>For Primary Care Networks (PCNs) to be successful they will need to work in partnership with local people and the communities they serve. NHS England does have a statutory duty to undertake an annual assessment of clinical commissioning groups’ (CCGs) performance, as part of the CCG Improvement and Assessment Framework (IAF). One of the indicators assessed is patient and community engagement. All NHS service providers, including general practitioner practices, have legal duties to engage with local authority health scrutiny about changes which may be considered substantial. These duties which currently apply to NHS service providers and commissioners around engagement and consultation will continue to be valid.</p><p>Further information on the IAF is available on the NHS England website at the following link:</p><p><a href="https://www.england.nhs.uk/commissioning/regulation/ccg-assess/" target="_blank">https://www.england.nhs.uk/commissioning/regulation/ccg-assess/</a></p><p>Results from the assessments are published on ‘MyNHS’ at the following link:</p><p><a href="https://www.nhs.uk/service-search/performance-indicators/organisations/ccg-year-end-2015-assurance-assessment" target="_blank">https://www.nhs.uk/service-search/performance-indicators/organisations/ccg-year-end-2015-assurance-assessment</a></p><p>The assessments made are in line with the document ‘Patient and public participation in commissioning health and care: statutory guidance for CCGs and NHS England’, which is at the following link:</p><p><a href="https://www.england.nhs.uk/publication/patient-and-public-participation-in-commissioning-health-and-care-statutory-guidance-for-ccgs-and-nhs-england/" target="_blank">https://www.england.nhs.uk/publication/patient-and-public-participation-in-commissioning-health-and-care-statutory-guidance-for-ccgs-and-nhs-england/</a></p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 20/06/2019 15:40:56 answering member 4455 label Biography information for Seema Kennedy
tabling member	4249 label Biography information for Anne Marie Morris